Results 81 to 90 of about 67,411 (205)

Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer

Journal of Clinical Oncology, 2020
PURPOSE Differentiating the irinotecan dose on the basis of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype improves the pathologic complete response (pCR) rate.
Ji Zhu, A. Liu, Xinchen Sun, Luying Liu, Yaqun Zhu, Tao Zhang, J. Jia, Shisheng Tan, Junxin Wu, Xin Wang, Juying Zhou, Jialin Yang, Chen Zhang, Hongyan Zhang, Yuanyuan Zhao, G. Cai, Wei Zhang, F. Xia, J. Wan, Hui Zhang, L. Shen, S. Cai, Zhen Zhang   +22 more
semanticscholar   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, EarlyView.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

Management of severe capecitabine-induced corneal toxicity

American Journal of Ophthalmology Case Reports
Purpose: To describe the clinical presentation and management of severe capecitabine-induced corneal toxicity. Observations: A 71-year-old woman presented with severe bilateral vision loss. Four months earlier, capecitabine was initiated for a metastatic
Mathieu Heyvaert, Hannelore Denys, Jo Van Dorpe, Dimitri Roels   +3 more
doaj   +1 more source

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Journal for ImmunoTherapy of Cancer, 2020
Background Response rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy.
A. Shah, L. Flaum, I. Helenowski, C. Santa-Maria, Sarika Jain, A. Rademaker, Valerie M Nelson, Dean Tsarwhas, M. Cristofanilli, W. Gradishar   +9 more
semanticscholar   +1 more source

The Prognostic Value of EDRIC and Its Association With Radiation‐Induced Lymphopenia in Patients With Esophageal Cancer Undergoing Radical Radiotherapy: A Single‐Center Chinese Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study aimed to evaluate the predictive value of the estimated dose of radiation to immune cells (EDRIC) in patients with esophageal cancer receiving radical radiotherapy. We retrospectively reviewed the data of patients with esophageal cancer who underwent definitive radiotherapy at our institution.
Yue Ke, Chen Yang, Yu‐Xing Li, Xiao‐Xiao Liu, Xiao Liu, Jia‐Min Gao, Hong‐Bing Ma   +6 more
wiley   +1 more source

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

BMC Cancer, 2022
Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the
Shigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, Shu Yazaki, Toshihiro Okuya, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kan Yonemori   +11 more
doaj   +1 more source

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Annals of Oncology, 2018
Background Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2.
N. Boku, M. Ryu, Ken Kato, H. Chung, K. Minashi, K. Lee, H. Cho, W. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, L.-T. Chen, L.-T. Chen, Yoon-Koo Kang   +16 more
semanticscholar   +1 more source

Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti‐Tumor Drug Delivery

Macromolecular Rapid Communications, EarlyView.
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley   +1 more source

Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study

Breast
Purpose: To determine the beneficiaries of capecitabine in patients with triple-negative breast cancer (TNBC) who failed to achieve pathological complete response (pCR) by analyzing the efficacy of the drug in different HER2 statuses and TNM stages ...
Youzhao Ma, Mingda Zhu, Jingyang Zhang, Dechuang Jiao, Yangyang Hou, Xiuchun Chen, Zhenzhen Liu   +6 more
doaj   +1 more source

Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome

Scientific Reports, 2021
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogenesis.
Shiori Hiromoto, Takehiro Kawashiri, Natsumi Yamanaka, Daisuke Kobayashi, Keisuke Mine, Mizuki Inoue, Mayako Uchida, Takao Shimazoe   +7 more
doaj   +1 more source